Skip to main content
padlock icon - secure page this page is secure

Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study

Buy Article:

$52.00 + tax (Refund Policy)

Summary Objective and design 

Most cases of euvolaemic hyponatraemia are associated with elevated plasma levels of AVP. Conivaptan is a high-affinity, nonpeptide vasopressin V1A/V2-receptor antagonist. We performed a subgroup analysis of a multicentre, randomized, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy and safety of intravenous (i.v.) conivaptan for the treatment of euvolaemic hyponatraemia. Patients 

Fifty-six euvolaemic patients with serum [Na+] of 115 to < 130 mmol/l received conivaptan 40 or 80 mg/day or placebo via continuous i.v. infusion for 4 days. A 20-mg loading dose was administered intravenously over 30 min in the conivaptan groups; the placebo group received a placebo loading dose. Measurements 

Change in serum [Na+], measured by the baseline-adjusted area under the serum [Na+]–time curve (AUC), was the primary efficacy parameter. Secondary efficacy measures included the time from the first dose to a confirmed ≥ 4 mmol/l increase in serum [Na+], total time with serum [Na+] ≥ 4 mmol/l above baseline, change in serum [Na+] from baseline, and number of patients with a confirmed ≥ 6 mmol/l increase in serum [Na+] or normal [Na+]. Safety assessments included adverse events (AE), incidence of overly rapid correction of serum [Na+], and changes in vital signs and electrocardiographic and clinical laboratory parameters. Results 

During the first 2 days of treatment, and over the entire 4-day treatment period, both conivaptan doses significantly increased the serum [Na+] AUC more than placebo (P < 0·01). Conivaptan 40 and 80 mg/day significantly improved all secondary efficacy measures. Conivaptan was generally well tolerated; infusion-site reaction was the most common AE. Conclusions 

In hospitalized patients with euvolaemic hyponatraemia, i.v. conivaptan significantly increased serum [Na+] promptly and was well tolerated.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Research Article

Affiliations: 1: Department of Medicine, Georgetown University, Washington, DC, USA, 2: Department of Internal Medicine ‘D’, Sourasky Medical Center, Tel Aviv, Israel and 3: Astellas Pharma US, Inc., Deerfield, IL, USA

Publication date: July 1, 2008

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more